Literature DB >> 23591322

Haematological cancer: Indolent lymphoma--why not to sprint at the start of a marathon.

Stephane Doucet, Leo I Gordon.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23591322     DOI： 10.1038/nrclinonc.2013.53

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  8 in total

1.  Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial.

Authors:  Marinus H J van Oers; Richard Klasa; Robert E Marcus; Max Wolf; Eva Kimby; Randy D Gascoyne; Andrew Jack; Mars Van't Veer; Andrej Vranovsky; Harald Holte; Martine van Glabbeke; Ivana Teodorovic; Cynthia Rozewicz; Anton Hagenbeek
Journal:  Blood       Date:  2006-07-27       Impact factor: 22.113

2.  Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.

Authors:  Mathias J Rummel; Norbert Niederle; Georg Maschmeyer; G Andre Banat; Ulrich von Grünhagen; Christoph Losem; Dorothea Kofahl-Krause; Gerhard Heil; Manfred Welslau; Christina Balser; Ulrich Kaiser; Eckhart Weidmann; Heinz Dürk; Harald Ballo; Martina Stauch; Fritz Roller; Juergen Barth; Dieter Hoelzer; Axel Hinke; Wolfram Brugger
Journal:  Lancet       Date:  2013-02-20       Impact factor: 79.321

3.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

Authors:  Gilles Salles; John Francis Seymour; Fritz Offner; Armando López-Guillermo; David Belada; Luc Xerri; Pierre Feugier; Réda Bouabdallah; John Vincent Catalano; Pauline Brice; Dolores Caballero; Corinne Haioun; Lars Moller Pedersen; Alain Delmer; David Simpson; Sirpa Leppa; Pierre Soubeyran; Anton Hagenbeek; Olivier Casasnovas; Tanin Intragumtornchai; Christophe Fermé; Maria Gomes da Silva; Catherine Sebban; Andrew Lister; Jane A Estell; Gustavo Milone; Anne Sonet; Myriam Mendila; Bertrand Coiffier; Hervé Tilly
Journal:  Lancet       Date:  2010-12-20       Impact factor: 79.321

Review 4.  Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials.

Authors:  Liat Vidal; Anat Gafter-Gvili; Leonard Leibovici; Martin Dreyling; Michele Ghielmini; Shu-Fang Hsu Schmitz; Amos Cohen; Ofer Shpilberg
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

5.  Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study.

Authors:  Brad S Kahl; Nancy L Bartlett; John P Leonard; Ling Chen; Kristen Ganjoo; Michael E Williams; Myron S Czuczman; K Sue Robinson; Robin Joyce; Richard H van der Jagt; Bruce D Cheson
Journal:  Cancer       Date:  2010-01-01       Impact factor: 6.860

6.  Follicular lymphoma in the United States: first report of the national LymphoCare study.

Authors:  Jonathan W Friedberg; Michael D Taylor; James R Cerhan; Christopher R Flowers; Hildy Dillon; Charles M Farber; Eric S Rogers; John D Hainsworth; Elaine K Wong; Julie M Vose; Andrew D Zelenetz; Brian K Link
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Bendamustine, but not fludarabine, exhibits a low stem cell toxicity in vitro.

Authors:  M Schmidt-Hieber; A Busse; B Reufi; W Knauf; E Thiel; I W Blau
Journal:  J Cancer Res Clin Oncol       Date:  2008-08-22       Impact factor: 4.553

8.  Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.

Authors:  Florent Malard; Nicolaus Kröger; Ian H Gabriel; Kai Hübel; Jane F Apperley; Grzegorz W Basak; Kenneth W Douglas; Catarina Geraldes; Ozren Jaksic; Zdenek Koristek; Francesco Lanza; Roberto Lemoli; Gabor Mikala; Dominik Selleslag; Nina Worel; Mohamad Mohty; Rafael F Duarte
Journal:  Biol Blood Marrow Transplant       Date:  2011-10-13       Impact factor: 5.742
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.